114 related articles for article (PubMed ID: 36478221)
1. Intratumoral Gene Transfer of mRNAs Encoding IL12 in Combination with Decoy-Resistant IL18 Improves Local and Systemic Antitumor Immunity.
Cirella A; Bolaños E; Di Trani CA; de Andrea CE; Sánchez-Gregorio S; Etxeberria I; Gonzalez-Gomariz J; Olivera I; Brocco D; Glez-Vaz J; Luri-Rey C; Azpilikueta A; Rodríguez I; Fernandez-Sendín M; Egea J; Eguren I; Sanmamed MF; Palencia B; Teijeira A; Berraondo P; Melero I
Cancer Immunol Res; 2023 Feb; 11(2):184-198. PubMed ID: 36478221
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-18 in cancer immunology and immunotherapy.
Cirella A; Olivera I; Luri-Rey C; Bolaños E; Berraondo P; Melero I
Expert Opin Ther Targets; 2023; 27(11):1035-1042. PubMed ID: 37993172
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment.
Hewitt SL; Bailey D; Zielinski J; Apte A; Musenge F; Karp R; Burke S; Garcon F; Mishra A; Gurumurthy S; Watkins A; Arnold K; Moynihan J; Clancy-Thompson E; Mulgrew K; Adjei G; Deschler K; Potz D; Moody G; Leinster DA; Novick S; Sulikowski M; Bagnall C; Martin P; Lapointe JM; Si H; Morehouse C; Sedic M; Wilkinson RW; Herbst R; Frederick JP; Luheshi N
Clin Cancer Res; 2020 Dec; 26(23):6284-6298. PubMed ID: 32817076
[TBL] [Abstract][Full Text] [Related]
4. Optimization of T-cell Receptor-Modified T Cells for Cancer Therapy.
Drakes DJ; Rafiq S; Purdon TJ; Lopez AV; Chandran SS; Klebanoff CA; Brentjens RJ
Cancer Immunol Res; 2020 Jun; 8(6):743-755. PubMed ID: 32209638
[TBL] [Abstract][Full Text] [Related]
5. IL12/18/21 Preactivation Enhances the Antitumor Efficacy of Expanded γδT Cells and Overcomes Resistance to Anti-PD-L1 Treatment.
Teo HY; Song Y; Yong KSM; Liu Y; Mei Y; Hanafi ZB; Zhu Y; Chua YL; Gascoigne NRJ; Chen Q; Liu H
Cancer Immunol Res; 2023 Jul; 11(7):978-999. PubMed ID: 37099651
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma.
Bhatia S; Longino NV; Miller NJ; Kulikauskas R; Iyer JG; Ibrani D; Blom A; Byrd DR; Parvathaneni U; Twitty CG; Campbell JS; Le MH; Gargosky S; Pierce RH; Heller R; Daud AI; Nghiem P
Clin Cancer Res; 2020 Feb; 26(3):598-607. PubMed ID: 31582519
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral Electroporation of Plasmid Encoded IL12 and Membrane-Anchored Anti-CD3 Increases Systemic Tumor Immunity.
Han M; Nguyen B; Lee JY; Browning E; Zhang J; Mukhopadhyay A; Gujar R; Salazar J; Hermiz R; Svenson L; Rolig AS; Redmond WL; Algazi AP; Daud AI; Canton DA; Twitty CG
Mol Cancer Res; 2022 Jun; 20(6):983-995. PubMed ID: 35302641
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy.
Alvarez M; Molina C; De Andrea CE; Fernandez-Sendin M; Villalba M; Gonzalez-Gomariz J; Ochoa MC; Teijeira A; Glez-Vaz J; Aranda F; Sanmamed MF; Rodriguez-Ruiz ME; Fan X; Shen WH; Berraondo P; Quintero M; Melero I
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34824158
[TBL] [Abstract][Full Text] [Related]
9. Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells.
Bae EA; Seo H; Kim BS; Choi J; Jeon I; Shin KS; Koh CH; Song B; Kim IK; Min BS; Han YD; Shin SJ; Kang CY
Cancer Res; 2018 Sep; 78(18):5315-5326. PubMed ID: 30012672
[TBL] [Abstract][Full Text] [Related]
10. Strict requirement for vector-induced type I interferon in efficacious antitumor responses to virally encoded IL12.
Melero I; Quetglas JI; Reboredo M; Dubrot J; Rodriguez-Madoz JR; Mancheño U; Casales E; Riezu-Boj JI; Ruiz-Guillen M; Ochoa MC; Sanmamed MF; Thieblemont N; Smerdou C; Hervas-Stubbs S
Cancer Res; 2015 Feb; 75(3):497-507. PubMed ID: 25527611
[TBL] [Abstract][Full Text] [Related]
11. mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy.
Olivera I; Bolaños E; Gonzalez-Gomariz J; Hervas-Stubbs S; Mariño KV; Luri-Rey C; Etxeberria I; Cirella A; Egea J; Glez-Vaz J; Garasa S; Alvarez M; Eguren-Santamaria I; Guedan S; Sanmamed MF; Berraondo P; Rabinovich GA; Teijeira A; Melero I
Cell Rep Med; 2023 Mar; 4(3):100978. PubMed ID: 36933554
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy.
Narvaiza I; Mazzolini G; Barajas M; Duarte M; Zaratiegui M; Qian C; Melero I; Prieto J
J Immunol; 2000 Mar; 164(6):3112-22. PubMed ID: 10706701
[TBL] [Abstract][Full Text] [Related]
13. Combined Tbet and IL12 gene therapy elicits and recruits superior antitumor immunity in vivo.
Qu Y; Chen L; Lowe DB; Storkus WJ; Taylor JL
Mol Ther; 2012 Mar; 20(3):644-51. PubMed ID: 22215017
[TBL] [Abstract][Full Text] [Related]
14. Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling.
Bowers JS; Nelson MH; Kundimi S; Bailey SR; Huff LW; Schwartz KM; Cole DJ; Rubinstein MP; Paulos CM
Clin Cancer Res; 2015 Jun; 21(11):2546-57. PubMed ID: 25904754
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
[No Abstract] [Full Text] [Related]
16. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
[TBL] [Abstract][Full Text] [Related]
17. Combination of interleukin 12 and interferon alpha gene therapy induces a synergistic antitumor response against colon and renal cell carcinoma.
Mendiratta SK; Quezada A; Matar M; Thull NM; Bishop JS; Nordstrom JL; Pericle F
Hum Gene Ther; 2000 Sep; 11(13):1851-62. PubMed ID: 10986558
[TBL] [Abstract][Full Text] [Related]
18. Administration route- and immune cell activation-dependent tumor eradication by IL12 electrotransfer.
Li S; Zhang L; Torrero M; Cannon M; Barret R
Mol Ther; 2005 Nov; 12(5):942-9. PubMed ID: 15953768
[TBL] [Abstract][Full Text] [Related]
19. Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models.
Xu C; Zhang Y; Rolfe PA; Hernández VM; Guzman W; Kradjian G; Marelli B; Qin G; Qi J; Wang H; Yu H; Tighe R; Lo KM; English JM; Radvanyi L; Lan Y
Clin Cancer Res; 2017 Oct; 23(19):5869-5880. PubMed ID: 28679778
[No Abstract] [Full Text] [Related]
20. CD8+ T cells stimulated by exosomes derived from RenCa cells mediate specific immune responses through the FasL/Fas signaling pathway and, combined with GM‑CSF and IL‑12, enhance the anti‑renal cortical adenocarcinoma effect.
Xu HY; Li N; Yao N; Xu XF; Wang HX; Liu XY; Zhang Y
Oncol Rep; 2019 Aug; 42(2):866-879. PubMed ID: 31233203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
